Chimeric Therapeutics Limited (ASX:CHM)

Market Cap	354.39K -96.4%
Revenue (ttm)	-189.85K
Net Income	-18.81M
EPS	-0.61
Shares Out	118.13M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	25,127,056
Open	0.0040
Previous Close	0.0030
Day's Range	0.0030 - 0.0040
52-Week Range	0.0030 - 0.4000
Beta	0.88
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 4, 2026

About Chimeric Therapeutics

Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies for oncology in Australia. The company develops CHM CDH17-directed CAR T cell therapy for the treatment of advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors; and CHM CLTX, a chlorotoxin-directed CAR T cell therapy to treat patients with recurrent or progressive glioblastoma and membrane-bound matrix metalloproteinase-2 (MMP2) expressing solid tumors. It also develops CHM CORE-NK for the treat...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2020
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: CHM

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 19, 2026

Data Sources Report a data error